NCT04246684: Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients |
|
|
| Active, not recruiting | 3 | 702 | Europe | Oxaliplatin, 85 mg/m2, Control arm, 5FU; 2400 mg/m2, 5-FU, control arm, 5FU, 250 mg/m2, Experimental arm: 5-FU, 5FU, 2400 mg/m2, experimental arm, Oxaliplatin 50 mg/m2, Experimental arm, Folinic Acid, 400 mg/m2, Folinic Acid, Radiotherapy control, 5x5 Gy: 25 Gy, Capecitabine, 1000 mg/m2, Capecitabine, Oxaliplatin 85 mg/m2, radiotherapy experimental, 30 x 1,8 Gy: 54 Gy, Capecitabine, 825 mg/m2, Oxaliplatin, 130 mg/m2, Oxaliplatin | Prof. Dr. med. Claus Rödel | Rectal Cancer Stage III | 09/23 | 09/28 | | |
INFINITY, NCT04389541: Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology |
|
|
| Completed | N/A | 499 | Europe | | iOMEDICO AG, Bristol-Myers Squibb, Roche Pharma AG | Advanced Solid Tumors or Hematologic Malignancies | 06/23 | 06/23 | | |
| Recruiting | N/A | 1100 | Europe | | Jena University Hospital, University Hospital Dresden, Novartis, Swedish Orphan Biovitrum, Grifols Biologicals, LLC, Amgen, argenx | Immune Thrombocytopenia | 09/26 | 04/27 | | |
